News und Analysen
What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today
After the company announced it has filed for approval with New Zealand regulators to begin phase 1 studies of its hepatitis B RNAi therapy, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)....
2018's 3 Biggest Catalysts for Marijuana Stocks
Forget seeing marijuana stocks go up in smoke in 2017. They've been smoking hot.According to cannabis research firm ArcView, the North American legal weed industry is expected to grow by 26% a....
3 Best Marijuana Biotech Stocks for 2018
Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. But that milestone means little for biotechs....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis, Inc. (NASDAQ: EXEL) has already delivered big gains this year, but there could be a few untapped veins in this biotech gold mine. We'll need to tread lightly because a great deal of....
Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer
After reporting in 2016 that its second-line kidney cancer drug, Cabometyx, outperformed Pfizer Inc.'s (NYSE: PFE) top-selling Sutent in first-line advanced kidney cancer patients, Exelixis....
The FDA Just Approved a Game-Changing Therapy for Blindness
A decision on Spark Therapeutics' (NASDAQ: ONCE) vision-restoring gene therapy, Luxturna, was expected next month, but the Food and Drug Administration decided an early OK was warranted following....
Why Juno Therapeutics Stock Fell Last Week
Juno Therapeutics (NASDAQ: JUNO) reported some pretty good data at last week's American Society of Hematology conference, but the stock bombed shortly after.In this clip from Industry Focus:....
3 Questions Keeping Juno Therapeutics' Investors Up at Night
Juno Therapeutics (NASDAQ: JUNO) soared ahead of the high-profile American Society of Hematology conference earlier this month, but it's been tough going for investors ever since. The sell-off in....
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Controversial billionaire George Soros may no longer be actively managing his namesake fund, Soros Fund Management, but the fund's quarterly activity remains a focal point for investors. The Soros....
The 3 Best Biotech Stocks of 2017
Biotech stocks rocked in 2017. At least a lot of them did. The SPDR S&P Biotech ETF has chalked up a gain of 40% with only a couple of weeks left in the year -- twice the return of the S&P....
Alnylam Gets Some Welcome News
The FDA has agreed to allow Alnylam (NASDAQ: ALNY) and Sanofi (NYSE: SNY) to resume trials of their hemophilia therapy, fitusiran. Previously, these companies had to halt their fitusiran studies....
This Tiny Biotech Pins Hope on U.S. Approval
Amicus Therapeutics (NASDAQ: FOLD) already markets its Fabry disease drug Galafold overseas, and it hopes it will soon be able to help patients in the U.S., too. Yesterday, management reported....
ASH 2017 Recap: These Were the Big Winners and Losers
The American Society of Hematology's (ASH) conference is one of biopharma's biggest annual events. This year's meeting was packed with market-moving presentations, but perhaps the biggest....
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
Wall Street finally gave up some ground on Thursday, as the Dow Jones Industrials finished down more than 75 points. Major benchmarks generally posted modest losses of half a percent or less as....
Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a....
Why Genomic Health, Inc. Skyrocketed Today
Genomic Health (NASDAQ: GHDX) is up 21% at 1:12 p.m. EST Thursday after Bloomberg reported that the cancer test company is contemplating selling itself after receiving takeover interest.While it's....
Here's Why Everyone's So Excited About bluebird bio
Investors have seen bluebird bio's (NASDAQ: BLUE) share price skyrocket following impressive early-stage trial results for bb2121, a multiple myeloma gene therapy that's licensed to Celgene Corp.....
Why Goldman Sachs, Seagate Technology, and Tenet Healthcare Jumped Today
The stock market continued to climb on Tuesday, with the Dow and S&P 500 moving higher to record levels even as the Nasdaq Composite lagged behind. Investors were generally focused on the....
This Is Why Global Blood Therapeutics Inc. Is Sinking Today
In response to the company announcing data from a case study at the American Society of Hematology meeting in Atlanta, shares of Global Blood Therapeutics (NASDAQ: GBT), a clinical-stage biotech....
3 Reasons Spark Therapeutics Is a Buy After Its Crash
After Spark Therapeutics and competitor BioMarin Therapeutic (NASDAQ: BMRN) updated investors on the progress that they're making developing competing gene therapies for hemophilia, investors....
3 Top Healthcare Stocks to Buy in December
If you're looking to put some healthcare stocks in your portfolio this holiday season, then it could be a very good time to consider Welltower Inc (NYSE: HCN), Geron Corporation (NASDAQ: GERN),....
ASH 2017: CAR-T Wallops Blood Cancer
The American Society of Hematology (ASH) annual meeting this past weekend was chock-full of excitement, including an unexpected snowstorm in Atlanta and a slew of game-changing non-Hodgkin....
What Happened in the Stock Market Today
Stocks moved higher on Monday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closing at record highs.Data source: Yahoo! Finance.Telecom and tech....
What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
After the company presented data on its chimeric antigen receptor T-cell therapy (CAR-T), JCAR017, at the annual American Society of Hematology conference over the weekend, Juno Therapeutics....
Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a biotech developing gene therapies, fell hard this morning after the company reported hemophilia trial data that bodes well for rival BioMarin....